AAAAAA
Results:
1-14
|
Results: 14
Authors:
Joiner, MC
Marples, B
Lambin, P
Short, SC
Turesson, I
Citation: Mc. Joiner et al., Low-dose hypersensitivity: Current status and possible mechanisms, INT J RAD O, 49(2), 2001, pp. 379-389
Authors:
Casassus, P
Gibson, J
Joshua, DE
Matthews, J
Diaz, JC
Gertz, MA
Kyle, R
Leong, T
Oken, MM
Fritz, E
Ludwig, H
Corrado, C
Lastiri, F
Peest, D
Grosbois, B
Vela-Ojeda, J
Avvisati, G
Mandelli, F
Petrucci, MT
Capnist, G
Child, JA
Drayson, MT
Dunn, J
MacLennan, I
Mellstedt, H
Osterborg, A
Rodjer, S
Turesson, I
Westin, J
Bergsagel, D
Browman, GP
Shustik, C
Zee, B
Hjorth, M
Holmberg, E
Rodjer, S
Turesson, I
Westin, J
Alison, R
Clarke, M
Elphinstone, P
Evans, V
Gray, R
Hicks, C
James, S
MacKinnon, L
Peto, R
Richards, S
Wheatley, K
Blade, J
Fontanillas, M
San Miguel, J
Aitchison, R
Newland, AC
Cunningham, D
Malpas, J
Powles, RL
Montuoro, A
Jacobson, J
Salmon, S
Citation: P. Casassus et al., Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, BR J HAEM, 113(4), 2001, pp. 1020-1034
Authors:
Johnsson, AA
Jacobsson, M
Granstrom, G
Johansson, CB
Strid, KG
Turesson, I
Citation: Aa. Johnsson et al., A microradiographic investigation of cancellous bone healing after irradiation and hyperbaric oxygenation: A rabbit study, INT J RAD O, 48(2), 2000, pp. 555-563
Authors:
Carlomagno, F
Burnet, NG
Turesson, I
Nyman, J
Peacock, JH
Dunning, AM
Ponder, BAJ
Jackson, SP
Citation: F. Carlomagno et al., Comparison of DNA repair protein expression and activities between human fibroblast cell lines with different radiosensitivities, INT J CANC, 85(6), 2000, pp. 845-849
Authors:
Juliusson, G
Celsing, F
Turesson, I
Lenhoff, S
Adriansson, M
Malm, C
Citation: G. Juliusson et al., Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma, BR J HAEM, 109(1), 2000, pp. 89-96
Authors:
Seidel, C
Sundan, A
Hjorth, M
Turesson, I
Dahl, IMS
Abildgaard, N
Waage, A
Borset, M
Citation: C. Seidel et al., Serum syndecan-1: a new independent prognostic marker in multiple myeloma, BLOOD, 95(2), 2000, pp. 388-392
Authors:
Lenhoff, S
Hjorth, M
Holmberg, E
Turesson, I
Westin, J
Nielsen, JL
Wisloff, F
Brinch, L
Carlson, K
Carlson, M
Dahl, IM
Gimsing, P
Hippe, E
Johnsen, H
Lamvik, J
Lofvenberg, E
Nesthus, I
Rodjer, S
Citation: S. Lenhoff et al., Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study, BLOOD, 95(1), 2000, pp. 7-11
Authors:
Carlson, K
Larsson, A
Simonsson, B
Turesson, I
Westin, J
Ljunghall, S
Citation: K. Carlson et al., Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline creatinine (DPD) and serum ICTP, and an evaluation of the DPD osteocalcin and ICTP osteocalcin ratios, EUR J HAEMA, 62(5), 1999, pp. 300-306
Authors:
Hjorth, M
Holmberg, E
Rodjer, S
Turesson, I
Westin, J
Wisloff, F
Citation: M. Hjorth et al., Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades, EUR J HAEMA, 62(4), 1999, pp. 271-277
Authors:
Johnsson, AA
Sawaii, T
Jacobsson, M
Granstrom, G
Turesson, I
Citation: Aa. Johnsson et al., A histomorphometric study of bone reactions to titanium implants in irradiated bone and the effect of hyperbaric oxygen treatment, INT J O M I, 14(5), 1999, pp. 699-706
Authors:
Szecsi, PB
Riise, E
Roslund, LB
Engberg, J
Turesson, I
Buhl, L
Schafer-Nielsen, C
Citation: Pb. Szecsi et al., Identification of patient-specific peptides for detection of M-proteins and myeloma cells, BR J HAEM, 107(2), 1999, pp. 357-364
Authors:
Turesson, I
Abildgaard, N
Ahlgren, T
Dahl, IM
Holmberg, E
Hjorth, M
Nielsen, JL
Oden, A
Seidel, C
Waage, A
Westin, J
Wisloff, F
Citation: I. Turesson et al., Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors, BR J HAEM, 106(4), 1999, pp. 1005-1012
Authors:
Dahl, IMS
Turesson, I
Holmberg, E
Lilja, K
Citation: Ims. Dahl et al., Serum hyaluronan in patients with multiple myeloma: Correlation with survival and Ig concentration, BLOOD, 93(12), 1999, pp. 4144-4148
Authors:
Pasquali, S
Maqueo, JD
Vela, J
Kyle, RA
Leong, T
Fritz, E
Suciu, S
Palva, IP
Oivanen, T
Corrado, C
Lastiri, FJ
Peest, D
Kildahl-Andersen, O
Maniatis, A
Alison, R
Clarke, M
Evans, V
Gray, R
Greaves, E
Hall, E
Hicks, C
James, S
Peto, R
Richards, S
Sinclair, D
Tooth, A
Wheatley, K
Avvisati, G
Boccadoro, M
Bugliosi, R
Mandelli, F
Petrucci, MT
Pileri, A
Tribalto, M
Alexanian, R
Delasalle, KB
Child, J
Dunn, J
MacLennan, I
Milligan, D
Mellstedt, H
Osterborg, A
Hjorth, M
Holmberg, E
Rodjer, S
Westin, J
Kamiya, O
Shimizu, K
Bergsagel, DE
Shustik, C
Hippe, E
Kjaersgaard, E
Turesson, I
Westin, J
Riccardi, A
Ucci, G
Blade, J
Fontanillas, M
De Rosa, L
Montuoro, A
Bartolucci, AA
Omura, GA
Stagg, M
Salmon, S
Tangen, C
Jacobs, P
Wood, L
Levy, LM
Citation: S. Pasquali et al., Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials, J CL ONCOL, 16(12), 1998, pp. 3832-3842
Risultati:
1-14
|